CD-19 Antibody Global Market Report 2025

CD19 antibody is a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker primarily found on B cells. CD19 plays a crucial role in B cell development and is often overexpressed in B cell-related malignancies, including certain leukemias and lymphomas. These antibodies are widely used in immunotherapy, particularly in CAR-T cell therapy, to direct the immune system to attack CD19-expressing cancer cells.

The primary disease types in the CD19 antibody market include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and others. B-cell non-Hodgkin lymphoma originates in B lymphocytes, a type of white blood cell essential for immune defense. CD19 antibodies are classified into polyclonal and monoclonal types, with routes of administration including intravenous and subcutaneous delivery. Their applications span enzyme-linked immunosorbent assay (ELISA), flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and other diagnostic and research uses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The CD-19 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-19 antibody market statistics, including CD-19 antibody industry global market size, regional shares, competitors with a CD-19 antibody market share, detailed CD-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-19 antibody industry. This CD-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CD-19 antibody market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rise of immunotherapy, the increase in oncology research funding, the emergence of CAR-T cell therapies, the rise in healthcare awareness, and the expansion of personalized medicine.

The CD-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the growing demand for targeted cancer therapies, increasing adoption of smart cell therapies, rising prevalence of hematologic malignancies, expansion of healthcare access in emerging markets, and development of next-generation immunotherapies and improvement in biomanufacturing technologies. Major trends in the forecast period include advancements in antibody-drug conjugates, development of bispecific antibodies, integration of AI in antibody design, improvements in cell-cell therapy platforms, adoption of single-use bioreactors, the emergence of nanobody-based therapeutics, and automation in biologics manufacturing.

The forecast of 8.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. lymphoma treatment centers by driving up costs of CD19-targeting monoclonal antibodies imported from France and the UK, exacerbating B-cell malignancy treatment expenses and increasing immunotherapy burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of B-cell malignancies is expected to drive the growth of the CD19 antibody market. B-cell malignancies encompass a group of cancers originating from abnormal B lymphocytes, such as B-cell lymphomas and leukemias, which affect the immune system and lead to uncontrolled cell growth. Several factors contribute to the rising prevalence of these malignancies, including aging populations, genetic predisposition, environmental exposures, lifestyle changes, advancements in detection methods, and immune system alterations. CD19 antibodies play a crucial role in treating B-cell malignancies by specifically targeting the CD19 protein found on malignant B cells, effectively destroying them while sparing healthy cells and boosting the immune response. For example, in January 2024, the American Cancer Society reported that approximately 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,240 deaths. As a result, the growing incidence of B-cell malignancies is fueling the expansion of the CD19 antibody market.

Leading companies in the CD19 antibody market are focusing on technological innovations, such as genetically modified autologous T-cell immunotherapy, to improve cancer treatment effectiveness, particularly for hematologic malignancies. This therapy involves genetically engineering a patient's T cells to recognize and attack cancer cells before reintroducing them into the body to enhance immune response. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, received FDA approval for AUCATZYL (obecabtagene autoleucel) for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The treatment is designed to minimize toxicity and improve the persistence of therapeutic cells through controlled T-cell activation. It is administered as a split-dose infusion on days 1 and 10, with dosing tailored to individual patient needs based on bone marrow assessment.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Gracell Biotechnologies Inc. to strengthen its cell therapy pipeline. The acquisition aims to leverage Gracell Biotechnologies' innovative FasTCAR platform and expertise in developing CD19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc., a China-based clinical-stage biopharmaceutical company, focuses on discovering and developing cutting-edge cell therapies, reinforcing AstraZeneca's commitment to advancing cancer treatment options.

Major players in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in CD-19 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD-19 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
• 2) By Type: Polyclonal, Monoclonal
• 3) By Route Of Administration: Intravenous, Subcutaneous
• 4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
• Subsegments:
• 1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
• 2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
• 3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
• 4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.; Amgen Inc.; Bio-Rad Laboratories Inc.; Miltenyi Biotec GmbH; Abcam Plc; Kite Pharma Inc.; BioLegend Inc.; Xencor Inc.; Juno Therapeutics Inc.; BD Biosciences; Zenas BioPharma Inc.; Cell Signaling Technology Inc.; Santa Cruz Biotechnology Inc.; Novus Biologicals LLC; Tonbo Biosciences Inc.; Bio X Cell Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.